Milgrom Lionel R
Department of Chemistry, Imperial College of Science, Technology and Medicine, South Kensington, London SW7 2AZ, United Kingdom.
J Altern Complement Med. 2006 Apr;12(3):271-9. doi: 10.1089/acm.2006.12.271.
In two recent studies of double-blind placebo-controlled homeopathic provings, entanglement was reported to have occurred between verum and placebo arms of the trials. This contrasts directly with the entanglement-disrupting effects of blinding, recently proposed as the reason for the failure of randomized controlled trials (RCTs) to demonstrate unequivocally the efficacy of homeopathy. It is proposed here that such entanglement between remedy and placebo during these double-blind placebo controlled provings is the direct result of the blinding process.
A previously developed theoretical model of entanglement in homeopathy among patient, practitioner, and remedy (called PPR entanglement) was used in this investigation.
In agreement with the results from the proving studies, the model predicts that application of the double-blind RCT methodology to homeopathic provings leads to entanglement between both remedy and placebo arms of the trial.
These theoretical findings can be understood in terms of the act of blinding leading to loss of information because of quantum-like state superposition of the verum and placebo proving groups. This is compared to conclusions drawn from the well-known double-slit experiment of quantum physics, and quantum information processing. It leads to a suggestion for testing entanglement in homeopathic provings.
在最近两项双盲安慰剂对照顺势疗法验证研究中,据报道试验的真药组和安慰剂组之间发生了纠缠。这与最近提出的盲法的纠缠破坏效应直接相反,盲法被认为是随机对照试验(RCT)未能明确证明顺势疗法疗效的原因。本文提出,在这些双盲安慰剂对照验证过程中,药物与安慰剂之间的这种纠缠是盲法过程的直接结果。
本研究使用了先前开发的顺势疗法中患者、从业者和药物之间纠缠的理论模型(称为PPR纠缠)。
与验证研究结果一致,该模型预测,将双盲RCT方法应用于顺势疗法验证会导致试验的药物组和安慰剂组之间发生纠缠。
这些理论发现可以从盲法行为导致信息丢失的角度来理解,这是由于真药组和安慰剂验证组的类量子态叠加。这与量子物理学著名的双缝实验以及量子信息处理得出的结论进行了比较。它为测试顺势疗法验证中的纠缠提出了一个建议。